Subcutaneous Tarlatamab Shows Safety and Early Activity in Small Cell Lung Cancer
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
Tag: WCLC 2026
Longer Gaps Between Tarlatamab Doses Show Promise in Small Cell Lung Cancer
The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and ...
Radiation or Surgery After Dual Immunotherapy Fails to Extend Survival in Metastatic Lung Cancer
The Phase III LONESTAR trial found that adding radiation or surgery after nivolumab plus ipilimumab did not improve survival in ...
Antibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung Cancer
An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and a manageable safety profile in previously treated EGFR-mutated lung ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!